ClinicalTrials.gg
CompletedNCT02300298Updated Feb 11, 2025Results posted

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

A Phase 1 interventional study of Nintedanib and Docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 19
10 · median 16
Started
2014
with 2 others
Phase 1
9 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
10 of 19
Boehringer Ingelheim

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 1, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) \<1.5 m2 and locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line platinum- based chemotherapy

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 20 years or older at the date of
  2. Patients with body surface area (BSA)\<1.5 m2 at screening
  3. Patients with histologically/ confirmed locally advanced or adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy (patients with non-target lesion only are eligible) First line chemotherapy may include continuation or switch maintenance therapy. One prior and/or neoadjuvant chemotherapy is accepted.
  4. Patients who have of at least 3 months
  5. Patients who are (ECOG) performance status (PS) of 0 or 1 at screening
  6. Patients obtained written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP)and Japanese GCP

Exclusion criteria

Exclusion criteria:

  1. Patients who have received more than one (i.e., second or third line chemotherapy) for advanced or NSCLC (Prior monotherapies with an epidermal growth factor receptor tyrosine kinase inhibitors [EGFR-TKI]) or anaplastic lymphoma kinase (ALK) inhibitor can be allowed)
  2. Patients who have received previous therapy with other vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) inhibitors (other than bevacizumab) for the treatment of NSCLC at any time
  3. Patients who have received following treatments within 4 weeks prior to start of study therapy 1) Other drugs 2) Chemo-, hormone-, immunotherapy, or monoclonal antibody.
  4. Patients who have received molecular target therapy including EGFR TKIs and ALK inhibitors within 2 weeks prior to start of study therapy
  5. Patents who have received radiotherapy within the past 3 months (in the case of limited -field [e.g. brain or bone metastasis] radiotherapy with palliative intent), within 2 weeks) prior to start of study therapy
  6. Patients who not recovered therapy related toxicities from previous chemotherapy and/or radiotherapy (= grade 2 Adverse Event from previous treatment) at screening

further exclusion criteria may be applied

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Nintedanib plus Docetaxel

    patients to receive backbone chemotherapy and nintedanib

    Drug: Nintedanib · Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1

    DLT was defined as any of the following study drug related adverse events (AEs): * Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 non-haematological toxicity except transient electrolyte abnormality and isolated increase of gamma-glutamyltransferase (GGT); gastrointestinal toxicity, despite adequate supportive care * CTCAE grade 4 haematological toxicity; Neutrophil count decreased or white blood cell count (not associated with fever) for \>7 days despite adequate supportive treatment * CTCAE grade 4 febrile neutropenia with fever ≥38.5 degrees * CTCAE grade ≥2 alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) increase in conjunction with CTCAE grade ≥2 total bilirubin increase * Inability to resume nintedanib dosing within 14 days after stopping Investigators judged clinically as DLT after dose reduction and severity medically notable (CTCAE, version 3). Sponsor with safety review committee was allowed to confirm the adequacy of this judgment.

    Time frame: Cycle 1, from first administration of study medication up to 21 days thereafter.

Secondary outcomes

  1. Maximum Measured Concentration (Cmax) of Nintedanib

    This outcome measure presents the maximum measured concentration (Cmax) of nintedanib in plasma in cycle 1.

    Time frame: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.

  2. Cmax of Docetaxel

    This outcome measure presents the Cmax of docetaxel in plasma in cycles 1 and 2.

    Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

  3. Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)

    This outcome measure presents the area under the concentration-time curve of nintedanib over the time interval from 0 to time of the last quantifiable concentration in plasma (AUC0-tz) in cycle 1.

    Time frame: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 after first drug administration of docetaxel in cycle 1.

  4. AUC0-tz of Docetaxel

    This outcome measure presents AUC0-tz of docetaxel in plasma in cycles 1 and 2.

    Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

  5. Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)

    This outcome measure presents the Area under the concentration-time curve of nintedanib over the time interval from 0 extrapolated to infinity in plasma (AUC0-infinity) in cycle 1.

    Time frame: at 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.

  6. AUC0-infinity of Docetaxel

    This outcome measure presents the AUC0-infinity of docetaxel in plasma in cycles 1 and 2.

    Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

07

Results

Posted Aug 6, 2018

Participant flow

This is a single arm study but it was allowed to discontinue the docetaxel treatment and continue the nintedanib treatment.

Disposition for Nintedanib
Participant flow — Disposition for Nintedanib
MilestoneNintedanib Plus Docetaxel (Patient Disposition for Nintedanib)Nintedanib Plus Docetaxel (Patient Disposition for Docetaxel)
Started100
Completed00
Not completed100
Withdrew: Progressive disease100
Disposition for Docetaxel
Participant flow — Disposition for Docetaxel
MilestoneNintedanib Plus Docetaxel (Patient Disposition for Nintedanib)Nintedanib Plus Docetaxel (Patient Disposition for Docetaxel)
Started010
Completed00
Not completed010
Withdrew: Progressive disease06
Withdrew: Other adverse event04

Outcome measures

PrimaryNumber of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1

DLT was defined as any of the following study drug related adverse events (AEs): * Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 non-haematological toxicity except transient electrolyte abnormality and isolated increase of gamma-glutamyltransferase (GGT); gastrointestinal toxicity, despite adequate supportive care * CTCAE grade 4 haematological toxicity; Neutrophil count decreased or white blood cell count (not associated with fever) for \>7 days despite adequate supportive treatment * CTCAE grade 4 febrile neutropenia with fever ≥38.5 degrees * CTCAE grade ≥2 alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) increase in conjunction with CTCAE grade ≥2 total bilirubin increase * Inability to resume nintedanib dosing within 14 days after stopping Investigators judged clinically as DLT after dose reduction and severity medically notable (CTCAE, version 3). Sponsor with safety review committee was allowed to confirm the adequacy of this judgment.

Time frame:
Cycle 1, from first administration of study medication up to 21 days thereafter.
Reported as:
Number · Participants
Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1
ParticipantsNintedanib Plus Docetaxel
Total with DLTs - all grades2
Total with DLTs - grade 1/20
Total with DLTs - grade 3/4/52
Hepatobiliary disorders (hep. dis.) - all grades1
Hep. dis. - grade 1/21
Hep. dis. - grade 3/4/50
Hep. dis. - hyperbilirubinaemia - all grades1
Hep. dis. - hyperbilirubinaemia - grade 1/21
Hep. dis. - hyperbilirubinaemia - grades 3/4/50
Investigations (inv.) - all grades2
Inv. - grade 1/20
Inv. - grade 3/4/52
Inv. - ALT increased - all grades2
Inv. - ALT increased - grades 1/20
Inv. - ALT increased - grades 3/4/52
Inv. - AST increased - all grades2
Inv. - AST increased - grades 1/20
Inv. - AST increased - grades 3/4/52
SecondaryMaximum Measured Concentration (Cmax) of Nintedanib

This outcome measure presents the maximum measured concentration (Cmax) of nintedanib in plasma in cycle 1.

Time frame:
At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.
Reported as:
Geometric mean · nanogram (ng)/ millilitre (mL)
Maximum Measured Concentration (Cmax) of Nintedanib
nanogram (ng)/ millilitre (mL)Nintedanib Plus Docetaxel
Maximum Measured Concentration (Cmax) of Nintedanib65.1 ± 86.6
SecondaryCmax of Docetaxel

This outcome measure presents the Cmax of docetaxel in plasma in cycles 1 and 2.

Time frame:
just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
Reported as:
Geometric mean · nanogram (ng)/ millilitre (mL)
Cmax of Docetaxel
nanogram (ng)/ millilitre (mL)Nintedanib Plus Docetaxel
Cycle 12710 ± 37.6
Cycle 22680 ± 49.6
SecondaryArea Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)

This outcome measure presents the area under the concentration-time curve of nintedanib over the time interval from 0 to time of the last quantifiable concentration in plasma (AUC0-tz) in cycle 1.

Time frame:
At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 after first drug administration of docetaxel in cycle 1.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)
ng*h/mLNintedanib Plus Docetaxel
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)342 ± 59.8
SecondaryAUC0-tz of Docetaxel

This outcome measure presents AUC0-tz of docetaxel in plasma in cycles 1 and 2.

Time frame:
just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
Reported as:
Geometric mean · ng*h/mL
AUC0-tz of Docetaxel
ng*h/mLNintedanib Plus Docetaxel
Cycle 13080 ± 27.4
Cycle 23320 ± 29.8
SecondaryArea Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)

This outcome measure presents the Area under the concentration-time curve of nintedanib over the time interval from 0 extrapolated to infinity in plasma (AUC0-infinity) in cycle 1.

Time frame:
at 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)
ng*h/mLNintedanib Plus Docetaxel
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)381 ± 62.7
SecondaryAUC0-infinity of Docetaxel

This outcome measure presents the AUC0-infinity of docetaxel in plasma in cycles 1 and 2.

Time frame:
just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
Reported as:
Geometric mean · ng*h/mL
AUC0-infinity of Docetaxel
ng*h/mLNintedanib Plus Docetaxel
Cycle 13320 ± 26.2
Cycle 23590 ± 26.6

Adverse events

Collected over From the first administration of docetaxel up to 28 days after the day of the last administration of study medication (docetaxel and/or nintedanib) up to 1002 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib Plus Docetaxel0/10 (0%)6/10 (60%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventNintedanib Plus Docetaxel
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/10
FatigueGeneral disorders1/10
Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Paraneoplastic pleural effusionRespiratory, thoracic and mediastinal disorders1/10
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Most frequent other events
Showing 10 of 68
Most frequent other events
EventNintedanib Plus Docetaxel
Neutrophil count decreasedInvestigations10/10
White blood cell count decreasedInvestigations10/10
AlopeciaSkin and subcutaneous tissue disorders9/10
Alanine aminotransferase increasedInvestigations8/10
Aspartate aminotransferase increasedInvestigations7/10
ConstipationGastrointestinal disorders5/10
DiarrhoeaGastrointestinal disorders5/10
NauseaGastrointestinal disorders5/10
FatigueGeneral disorders4/10
Gamma-glutamyltransferase increasedInvestigations4/10

Baseline characteristics

Treated set included all patients who were dispensed study medication and were documented to have taken at least one dose of study treatment (docetaxel or nintedanib).

Age, Continuous
Age, Continuous(Years)Nintedanib Plus Docetaxel
Mean67.30 ± 6.98
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib Plus Docetaxel
Female8
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nintedanib Plus Docetaxel
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib Plus Docetaxel
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • 1199.90.81001 Boehringer Ingelheim Investigational Site
    Chiba , Kashiwa, Japan
  • 1199.90.81003 Boehringer Ingelheim Investigational Site
    Kanagawa, Yokohama, Japan
  • 1199.90.81007 Boehringer Ingelheim Investigational Site
    Osaka, Osakasayama, Japan
  • 1199.90.81006 Boehringer Ingelheim Investigational Site
    Osaka, Osaka, Japan
  • 1199.90.81004 Boehringer Ingelheim Investigational Site
    Shizuoka, Sunto-gun, Japan
  • 1199.90.81002 Boehringer Ingelheim Investigational Site
    Tokyo, Chuo, Japan
09

References and documents

Publications

  • Yamamoto N, Kenmotsu H, Goto K, Takeda K, Kato T, Takeda M, Horinouchi H, Saito I, Sarashina A, Tanaka T, Morsli N, Nakagawa K. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. Cancer Chemother Pharmacol. 2018 Oct;82(4):685-694. doi: 10.1007/s00280-018-3649-x. Epub 2018 Aug 3. PubMed 30073583 ↗

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jan 2016, 12 months.

Results were first posted in Aug 2018, 2 years 6 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 12 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2014
First posted
Nov 25, 2014
StartActual
Dec 24, 2014
Primary completionActual
Jan 15, 2016
CompletionActual
Oct 27, 2017
Results first posted
Aug 6, 2018
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02300298
Responsible party
Sponsor
First posted
Nov 25, 2014
Start date
Dec 24, 2014
Primary completion
Jan 15, 2016
Completion
Oct 27, 2017
Results posted
Aug 6, 2018
Last update
Feb 11, 2025

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Docetaxel

Start the discussion